Cutler Group LP Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Jan 18, 2024	BUY	$20.27 - $42.44 $253,375 - $530,500	12,500 New	12,500 $0
Q2 2023 Jul 18, 2023	SELL	$23.9 - $35.38 $33,460 - $49,532	-1,400 Reduced 53.85%	1,200 $3,000
Q1 2023 May 01, 2023	BUY	$22.82 - $35.32 $59,332 - $91,832	2,600 New	2,600 $11,000
Q4 2021 Jan 18, 2022	SELL	$29.21 - $44.64 $46,736 - $71,424	-1,600 Reduced 44.44%	2,000 $0
Q3 2021 Oct 26, 2021	SELL	$21.26 - $38.85 $82,914 - $151,515	-3,900 Reduced 52.0%	3,600 $9,000
Q2 2021 Jul 19, 2021	BUY	$12.56 - $29.69 $94,200 - $222,675	7,500 New	7,500 $10,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.